In a world where technology is rapidly advancing, the use of innovative tools in healthcare is a topic that sparks both excitement and controversy. Let's dive into a fascinating discussion about leveraging technology in ADHD care, specifically focusing on a recent poster presentation at the APSARD 2026 Annual Conference. The future of ADHD diagnosis and treatment may just be a click away, but is it too good to be true?
Dr. Barry Herman, the Chief Medical Officer of Mentavi Health, shared his insights on an online asynchronous assessment tool for diagnosing ADHD in adults. This presentation addressed some critical questions surrounding the role of telehealth in ADHD diagnosis, especially in light of concerns about diagnostic accuracy and the use of stimulants.
But here's where it gets controversial... While telemedicine has expanded rapidly, it has also faced scrutiny. Dr. Herman aimed to fill a gap in the evidence by comparing the accuracy of their diagnostic evaluation with the current standard of care - a clinical interview by a licensed professional. The results, published in the Journal of Clinical Psychiatry, showed a high degree of agreement between the online assessment and the clinical interview, with an impressive 80% sensitivity and a positive predictive value of 95%.
However, the study also revealed a concerning false-positive rate of 12% for the online assessment, compared to 56% for clinicians conducting interviews. This highlights the variability in diagnostic approaches and the need for standardized practices. Many healthcare professionals, without sufficient expertise, are involved in ADHD diagnoses, emphasizing the importance of setting evidence-based standards.
And this is the part most people miss... Currently, there are no accessible biomarkers for ADHD diagnosis. We rely on the judgment of clinicians, which can vary widely. Dr. Herman's study is a significant step towards establishing a scientific foundation for telehealth and ADHD diagnosis, especially considering the high co-occurrence of ADHD with other psychiatric conditions.
The tool developed by Mentavi Health aims to account for diagnostic complexity by identifying commonly associated mental health conditions with ADHD. This information can assist clinicians in further exploring and understanding the clinical presentation of each patient.
Now, let's talk about AI... Many clinicians worry about artificial intelligence replacing human judgment. Dr. Herman emphasizes that their company takes a proactive approach, with an AI ethics committee in place. The diagnostic process involves real humans making clinical judgments based on the collected data, ensuring a human touch in the process.
Finally, a personal note from Dr. Herman: His motivation stems from a desire to help people and improve their lives. After spending time in the pharmaceutical industry, he returned to a role that allows him to make a direct impact on individual patient encounters.
This presentation at APSARD 2026 offers a glimpse into the potential of technology in ADHD care. While it raises important questions and challenges, it also showcases the progress being made in this field. Stay tuned for more insights and emerging data from the conference, as we navigate the exciting yet complex world of telehealth and ADHD diagnosis.
